Arcutis Biotherapeutics Inc (ARQT)

$10.2

-1.68

(-14.14%)

Market is closed - opens 7 PM, 15 Apr 2024

Insights on Arcutis Biotherapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 38.10M → 13.52M (in $), with an average decrease of 64.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -44.76M → -66.28M (in $), with an average decrease of 48.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.7% return, outperforming this stock by 74.3%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 248.2% return, outperforming this stock by 312.6%

Performance

  • $9.85
    $11.57
    $10.20
    downward going graph

    3.48%

    Downside

    Day's Volatility :14.91%

    Upside

    11.84%

    downward going graph
  • $1.76
    $15.40
    $10.20
    downward going graph

    82.75%

    Downside

    52 Weeks Volatility :88.57%

    Upside

    33.77%

    downward going graph

Returns

PeriodArcutis Biotherapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
193.95%
-1.1%
0.0%
6 Months
171.64%
6.7%
0.0%
1 Year
-27.04%
3.2%
-0.7%
3 Years
-64.44%
15.2%
-21.6%

Highlights

Market Capitalization
1.4B
Book Value
$0.92
Earnings Per Share (EPS)
-3.78
Wall Street Target Price
18.0
Profit Margin
0.0%
Operating Margin TTM
-452.23%
Return On Assets TTM
-38.12%
Return On Equity TTM
-175.79%
Revenue TTM
59.6M
Revenue Per Share TTM
0.86
Quarterly Revenue Growth YOY
356.8%
Gross Profit TTM
2.9M
EBITDA
-239.6M
Diluted Eps TTM
-3.78
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.51
EPS Estimate Next Year
-1.46
EPS Estimate Current Quarter
-0.77
EPS Estimate Next Quarter
-0.8

Analyst Recommendation

Buy
    78%Buy
    21%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Arcutis Biotherapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
13
13
Hold
3
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 76.47%

Current $10.20
Target $18.00

Technicals Summary

Sell

Neutral

Buy

Arcutis Biotherapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc
-4.32%
171.64%
-27.04%
-64.44%
-53.21%
Moderna, Inc.
Moderna, Inc.
1.24%
14.36%
-26.97%
-34.23%
306.89%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.2%
7.24%
10.36%
82.9%
140.93%
Novo Nordisk A/s
Novo Nordisk A/s
-5.94%
23.09%
45.57%
248.23%
394.48%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-2.73%
6.03%
21.0%
79.35%
117.3%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc
NA
NA
NA
-2.51
-1.76
-0.38
NA
0.92
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.2
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.28
26.28
1.51
44.87
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.38
3.35
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.64
28.64
0.54
16.78
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc
Buy
$1.4B
-53.21%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.0B
306.89%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$100.2B
140.93%
26.28
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$565.1B
394.48%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.8B
117.3%
28.64
36.68%

Institutional Holdings

  • Jennison Associates LLC

    7.89%
  • Suvretta Capital Management, LLC

    7.37%
  • Rubric Capital Management LP

    5.78%
  • Polar Capital Holdings PLC

    5.48%
  • Morgan Stanley - Brokerage Accounts

    5.29%
  • BlackRock Inc

    5.15%

Corporate Announcements

  • Arcutis Biotherapeutics Inc Earnings

    Arcutis Biotherapeutics Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.

Organization
Arcutis Biotherapeutics Inc
Employees
296
CEO
Mr. Todd Franklin Watanabe M.A.
Industry
Health Technology

FAQs